Quality Compounder

556 tickers in this investment thesis
Ranks this page's recent reports by score.
Stryker Corporation
SYK·Healthcare
A ★★★★Buy
Current$291.86
Target$338.10
Return+15.8%
Nov 1, 2026

Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.

Score
81
Linde plc
LIN·Materials
A ★★★★Buy
Current$514.24
Target$527.58
Return+2.6%
Nov 1, 2026

Linde combines durable industrial-gas contracts, pricing power and high returns on capital with a strong long-term compounding opportunity, although its premium valuation and capital-intensive expansion limit the margin of safety.

Score
77
Skyward Specialty Insurance Group, Inc.
SKWD·Financials
A ★★★★Buy
Current$59.04
Target$66.00
Return+11.8%
Nov 1, 2026

Skyward Specialty combines profitable niche underwriting with Apollo-driven international expansion and attractive forward earnings valuation, although reserve volatility, acquisition leverage, and insurance pricing competition remain meaningful risks.

Score
78
Exelixis, Inc.
EXEL·Healthcare
B ★★★Hold
Current$69.39
Target$65.45
Return-5.7%
Nov 1, 2026

Exelixis combines exceptional oncology cash generation and substantial buybacks with a promising second drug franchise, but CABOMETYX concentration and a historically elevated valuation limit the margin for regulatory disappointment.

Score
70
Acadian Asset Management Inc.
AAMI·Financials
B ★★★Hold
Current$88.92
Target$93.50
Return+5.2%
Nov 1, 2026

Acadian combines differentiated systematic investment expertise with accelerating institutional inflows and expanding margins, but its higher valuation and sensitivity to market-driven AUM fluctuations constrain near-term upside.

Score
68
Exponent, Inc.
EXPO·Industrials
A ★★★★Buy
Current$80.26
Target$87.29
Return+8.8%
Nov 1, 2026

Exponent combines specialist scientific expertise, exceptional capital returns, and accelerating consulting demand, but its premium earnings multiple and project-based revenue create sensitivity to growth disappointments.

Score
79
Covista Inc.
CVSA·Consumer Staples
A ★★★★Buy
Current$124.33
Target$145.60
Return+17.1%
Nov 1, 2026

Covista combines durable healthcare education demand, expanding online-program profitability, and strong cash generation at a reasonable valuation, although student-aid regulation and clinical capacity constraints could weaken growth.

Score
82
Federated Hermes, Inc.
FHI·Financials
A ★★★★Buy
Current$58.48
Target$66.00
Return+12.9%
Nov 1, 2026

Federated Hermes offers profitable, cash-generative asset management and shareholder returns at a modest valuation, although money market outflows, fee compression, and acquisition execution could limit earnings growth.

Score
78
Perimeter Solutions, Inc.
PRM·Materials
C ★★Sell
Current$28.06
Nov 1, 2026

Perimeter Solutions combines a defensible wildfire-retardant franchise with acquisition-led industrial diversification, but demanding cash-flow valuation, integration risk, and elevated leverage limit its near-term investment appeal.

Score
57
Axos Financial, Inc.
AX·Financials
A ★★★★Buy
Current$90.38
Target$108.00
Return+19.5%
Nov 1, 2026

Axos Financial combines efficient digital banking, strong returns on equity, and attractive earnings valuation with acquisition-driven growth opportunities, although specialty lending exposure and deposit-cost competition remain material risks.

Score
77
PriceSmart, Inc.
PSMT·Consumer Staples
B ★★★Hold
Current$165.70
Target$166.92
Return+0.7%
Nov 1, 2026

PriceSmart combines resilient membership economics with long-term Latin American warehouse expansion, but a premium earnings valuation and capital-intensive growth limit its margin of safety.

Score
66
ACI Worldwide, Inc.
ACIW·Technology
A ★★★★Buy
Current$56.34
Target$63.00
Return+11.8%
Nov 1, 2026

ACI Worldwide combines mission-critical payment software, recurring cash flow, and real-time payments growth opportunities at a reasonable valuation, although bookings volatility and Biller margin pressure could constrain earnings expansion.

Score
78